Scholar Rock Appoints Tony Kingsley to Its Board of Directors
May 21 2020 - 3:30PM
Business Wire
- Proven leader with extensive operational and
commercial experience joins expanded Board
Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical
company focused on the treatment of serious diseases in which
protein growth factors play a fundamental role, announced that Tony
Kingsley has been appointed to Scholar Rock’s Board of Directors as
a new independent director. Mr. Kingsley is a highly accomplished
leader with a successful track record of advancing companies in the
biotechnology, pharmaceutical, and medical device industries.
“I am thrilled to welcome Tony to our Board. He brings three
decades of experience in building and leading businesses from early
development through commercial launch and will be an invaluable
resource to the Board and the management team as we progress our
clinical programs in spinal muscular atrophy and cancer
immunotherapy,” said David Hallal, Chairman of the Board of Scholar
Rock. “Scholar Rock has a number of important milestones over the
next two years that could propel the Company into a new phase of
growth and would benefit from Tony’s expertise in operations,
commercialization, and strategy.”
“Scholar Rock has achieved significant momentum in applying
novel science and their unique platform to develop an impressive
portfolio of product candidates,” said Mr. Kingsley. “I am excited
to join the Company’s Board and contribute to their mission to
improve the lives of patients affected by neuromuscular disorders,
cancer, fibrosis, and anemia.”
Mr. Kingsley was most recently President and Chief Executive
Officer of Taris Bio, prior to its acquisition by Janssen
Pharmaceuticals at the end of 2019. Prior to Taris, he served as
President and Chief Operating Officer of The Medicines Company.
From 2010 to 2015, Mr. Kingsley led global commercial operations at
Biogen, Inc as Executive Vice President, delivering exceptional
growth through global product launches in multiple sclerosis
(Tecfidera® and PLEGRIDY®) and hemophilia (ALPROLIX® and
ELOCTATE®). Prior to Biogen, he held leadership roles in the
medical device industry, including senior vice president and
general manager of the gynecological surgical products business at
Hologic, Inc. and division president, diagnostic products at Cytyc
Corporation (now part of Hologic, Inc.), and was also a partner at
McKinsey & Company. He received a BA in government from
Dartmouth College and an MBA from Harvard Business School.
About Scholar Rock Scholar Rock is a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative medicines for the treatment of serious diseases in
which signaling by protein growth factors plays a fundamental role.
Scholar Rock is creating a pipeline of novel product candidates
with the potential to transform the lives of patients suffering
from a wide range of serious diseases, including neuromuscular
disorders, cancer, fibrosis and anemia. Scholar Rock’s approach to
targeting the molecular mechanisms of growth factor activation
enabled it to develop a proprietary platform for the discovery and
development of monoclonal antibodies that locally and selectively
target these signaling proteins at the cellular level. By
developing product candidates that act in the disease
microenvironment, the Company intends to avoid the historical
challenges associated with inhibiting growth factors for
therapeutic effect. Scholar Rock believes its focus on biologically
validated growth factors may facilitate a more efficient
development path. For more information, please visit
www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding the ability of new directors to
influence Scholar Rock’s progress, Scholar Rock’s ability to
develop its pipeline, including its product candidates, the
potential of Scholar Rock’s platform, and Scholar Rock’s growth
expectations. . The use of words such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“project,” “intend,” “future,” “potential,” or “continue,” and
other similar expressions are intended to identify such
forward-looking statements. All such forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include those risks more fully discussed in the
section entitled "Risk Factors" in Scholar Rock’s Quarterly Report
on Form 10-Q for the quarter ended March 31, 2020, as well as
discussions of potential risks, uncertainties, and other important
factors in Scholar Rock’s subsequent filings with the Securities
and Exchange Commission. Any forward-looking statements represent
Scholar Rock’s views only as of today and should not be relied upon
as representing its views as of any subsequent date. All
information in this press release is as of the date of the release,
and Scholar Rock undertakes no duty to update this information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200521005730/en/
Scholar Rock: Investors/Media Catherine Hu
chu@scholarrock.com 917-601-1649
Media: The Yates Network Kathryn Morris
kathryn@theyatesnetwork.com 914-204-6412
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024